granisetron and tamoxifen

granisetron has been researched along with tamoxifen in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baron, PL; Cole, DJ; Maize, JC; McClay, EF; McClay, ME; Metcalf, JS; Monroe, L; O'Brien, PH1
Goram, AL; Richmond, PL1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Sen, S; Sinha, N1
Dalvie, D; Loi, CM; Smith, DA1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1

Reviews

1 review(s) available for granisetron and tamoxifen

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for granisetron and tamoxifen

ArticleYear
The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
    British journal of cancer, 2000, Volume: 83, Issue:1

    Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Female; Follow-Up Studies; Granisetron; Humans; Life Tables; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Staging; Ondansetron; Prognosis; Risk; Skin Neoplasms; Survival Analysis; Tamoxifen; Treatment Outcome; Vomiting

2000

Other Studies

4 other study(ies) available for granisetron and tamoxifen

ArticleYear
Pegylated liposomal doxorubicin: tolerability and toxicity.
    Pharmacotherapy, 2001, Volume: 21, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diphenhydramine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Granisetron; Hematologic Diseases; Humans; Liposomes; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paresthesia; Premedication; Prochlorperazine; Ranitidine; Stomatitis; Tamoxifen; Treatment Failure

2001
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:2

    Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship

2011
Which metabolites circulate?
    Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:5

    Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations

2013